2m 2m 2m 2m 2m 2m 2m
Gelteq (GELS)
NASDAQ
$0.49-$0.0009 (-0.19%)
Price as of Jun 03, 2026 3:50 PM EDT- N/AMarket Cap
- -72.95%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Gelteq (GELS)
$0.49-$0.0009 (-0.19%)
Annual
Quarterly
06/30/2025 | 06/30/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 165,645 N/A | N/A N/A | |
Cost of Revenue | 115,397 N/A | N/A N/A | |
Gross Profit | 50,248 N/A | 0 N/A | |
Sales and Marketing Expense | 204,077 +1,021.30% | 18,200 N/A | |
Research and Development Expense | -628,606 +127.71% | -276,057 N/A | |
Depreciation and Amortization Expense | 1.2M +0.91% | 1.2M N/A | |
Total Operating Expenses | N/A N/A | N/A N/A | |
Operating Profit | -5.5M +86.54% | -2.9M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -1.9M +219.89% | -599,494 N/A | |
Interest Income and Expense and Net | -1.9M +219.89% | -599,494 N/A | |
Total Nonoperating Income and Expense | 403,393 +174.63% | 146,884 N/A | |
Income before Taxes | -6.6M +87.40% | -3.5M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -6.6M +87.40% | -3.5M N/A | |
Net Income from Continuing Operations Applicable to Common | -6.6M +87.40% | -3.5M N/A | |
Basic EPS and Net Income | -0.72 +63.64% | -0.44 N/A | |
Diluted EPS and Net Income | -0.72 +63.64% | -0.44 N/A | |
Basic Weighted Average Shares | 9.3M +14.22% | 8.1M N/A | |
Diluted Weighted Average Shares | 9.3M +14.22% | 8.1M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 344,648 +1,305.46% | 24,522 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 344,648 +1,305.46% | 24,522 N/A | |
Total Current Assets | 1.5M +396.88% | 303,227 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 15,907 -4.42% | 16,642 N/A | |
Total Long-Term Assets | 20.0M -2.38% | 20.5M N/A | |
Total Assets | 21.5M +3.46% | 20.8M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 4.2M +101.71% | 2.1M N/A | |
Total Current Liabilities | 5.6M +45.68% | 3.9M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 38,542 -97.83% | 1.8M N/A | |
Total Liabilities | 5.7M +0.45% | 5.6M N/A | |
Retained Earnings | N/A N/A | N/A N/A | |
Total Stockholders Equity | 15.8M +4.58% | 15.1M N/A | |
Total Shares Outstanding | N/A N/A | N/A N/A | |
Cash Flow | |||
Cash from Operating Activities | -5.5M +415.81% | -1.1M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -736,839 +397.29% | -148,170 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 6.5M +664.69% | 843,939 N/A | |
Financials Ratio | |||
Gross Margin | 30.33% N/A | N/A N/A | |
Operating Margin | -3,317.65% N/A | N/A N/A | |
Return on Assets | -31.47% N/A | N/A N/A | |
Return on Equity | -42.99% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.27 N/A | N/A N/A | |
Cash Ratio | 0.06 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow